In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition.
Szlam
Fania
F
Tanaka
Kenichi A
KA
Rumph
Brady
B
Bolliger
Daniel
D
Levy
Jerrold H
JH
D000244:Adenosine Diphosphate / Q000097:blood; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D000077144:Clopidogrel; D003029:Coagulants / Q000494:pharmacology*; D003094:Collagen / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D015942:Factor VIIa / Q000494:pharmacology*; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000494:pharmacology; D013917:Thrombin / Q000378:metabolism; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D003029:Coagulants; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D000244:Adenosine Diphosphate; D003094:Collagen; D000077144:Clopidogrel; C103587:recombinant FVIIa; D015942:Factor VIIa; D013917:Thrombin; D013988:Ticlopidine